OpenScience.ink

3 days ago • Molecular metabolism

Removing GIP receptors from excitatory brain cells does not stop GIP receptor blockers from speeding up weight loss caused by GLP-1Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism.

🥉 Top 5% JournalArticle

3 days ago • Psychiatry and clinical psychopharmacology

Could Incretin Receptor Agonists Be Used as Psychiatric Medicines Soon or Is That an Overstatement?Are Incretin Receptor Agonists Psychiatric Drugs: Near-term Opportunity or Creative Superlative?

Article

4 days ago • BMC cardiovascular disorders

Glucagon-like peptide-1 drugs and the risk of heart rhythm problems in people with heart attack and type 2 diabetesGlucagon-like peptide-1 receptor agonists and the risk of ventricular arrhythmia in patients with acute myocardial infarction and type 2 diabetes mellitus: a propensity score-matched cohort study.

📖 Top 30% JournalArticle

4 days ago • Medicina clinica

Benefits of semaglutide on daily activities and health in very old patients with heart failure, type 2 diabetes, and obesityActivities of daily living and health status benefits of semaglutide in very old patients with heart failure, type 2 diabetes, and obesity: Real-world practice study.

📖 Top 50% JournalArticle

4 days ago • Saudi journal of anaesthesia

Stomach contents in obese patients taking GLP-1 drugs measured by ultrasoundGastric residual volume in patients with obesity receiving GLP-1 receptor agonists: A comparative gastric ultrasound pilot study.

Article

4 days ago • Clinical kidney journal

Using one or several nutritional hormone receptor treatments for chronic kidney diseaseSingle or multiple nutritional hormone receptor modulators for chronic kidney disease.

🎖️ Top 10% JournalArticle

4 days ago • Journal of psychiatric research

Current clinical trials of incretin-based treatments for mental health conditionsIncretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov.

Article

4 days ago • Cureus

Nerve Pain Causing Chest and Abdominal Symptoms After Blood Sugar Drops with Tirzepatide TreatmentTreatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide.

Case Reports

4 days ago • Frontiers in pharmacology

GLP-1 drugs and DPP-4 inhibitors linked to memory loss in older adults with type 2 diabetesExploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort.

📖 Top 20% JournalArticle

4 days ago • Exploratory research in clinical and social pharmacy

How pharmacists help people stick to GLP-1 weight loss medicines by managing side effectsThe pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management.

📖 Top 50% JournalArticle

4 days ago • Saudi journal of anaesthesia

Managing patients on GLP-1 receptor drugs around surgery: Comparing international guidelinesPerioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.

Article

4 days ago • The lancet. Diabetes & endocrinology

Effectiveness and safety of oral orforglipron in Japanese people with obesityEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.

🥇 Top 1% JournalArticle

4 days ago • Saudi journal of anaesthesia

Guidelines for Managing Diabetes Drugs During Surgery for AnesthesiologistsPerioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.

Article

4 days ago • Metabolism: clinical and experimental

How Metabolism-Related Signals and Obesity Treatments Are Linked to Brain Changes and Nerve Cell LossThe metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration.

🥈 Top 2% JournalArticle

4 days ago • JAMA

Are GLP-1 Drugs Safe for People Who Are Frail?Analysis Asks: Are GLP-1 Drugs Safe in People With Frailty?

Article

4 days ago • The Journal of physiology

Time-restricted eating and strength training improve tirzepatide's effects on body fat and insulin sensitivity in female miceCombined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice.

🎖️ Top 10% JournalArticle

4 days ago • Alzheimer's & dementia (New York, N. Y.)

Combined buntanetap and dulaglutide reduce brain cell communication problems and memory loss in a mouse model of Alzheimer's diseaseCombined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.

🥉 Top 5% JournalArticle

4 days ago • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Metabolic, hormone, and reproductive changes linked to GLP-1 receptor drugs in women with high male hormones and insulin resistanceMetabolic, hormonal, and reproductive effects of GLP-1 receptor agonizts in hyperandrogenic insulin-resistant women: a systematic review.

📖 Top 30% JournalSystematic Review

4 days ago • Journal of the American Heart Association

Effects of Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure Patients with Normal Heart PumpingGlucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.

🥉 Top 5% JournalArticle

4 days ago • Expert review of clinical pharmacology

Using Diabetes Drugs Targeting GLP-1 Receptors as Possible Treatment for Substance Use DisordersFrom metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders.

📖 Top 20% JournalArticle

4 days ago • Med (New York, N.Y.)

Using Metabolic Profiles to Guide Alzheimer's and Parkinson's Disease Trials Based on Disease MechanismsMetabolic endotyping for mechanism-informed Alzheimer's and Parkinson's disease trials.

🥈 Top 2% JournalArticle

5 days ago • Frontiers in endocrinology

Comparing new blood sugar drugs and their effects on heart and kidney health in people with type 2 diabetes and heart failureNetwork and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failure.

🎖️ Top 10% JournalSystematic Review

5 days ago • JPGN reports

Widespread gallbladder lining growth after treatment with teduglutide: A case reportDiffuse gallbladder epithelial proliferation after teduglutide exposure: A case report.

Article

5 days ago • Cureus

Effects of Glucagon-Like Peptide-1 Drugs on Reproduction and Women's Health in Polycystic Ovary SyndromeReproductive and Gynecologic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Women With Polycystic Ovary Syndrome: A Scoping Review.

Article

5 days ago • Journal of vascular surgery

GLP-1 Receptor Agonists May Lower Rupture Risk, Heart Problems, and Death in Patients with Abdominal Aortic AneurysmsGLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.

🥉 Top 5% JournalArticle

5 days ago • Journal of the neurological sciences

Glucagon-like peptide-1 as a recovery marker after brain injury in people with obesity: Early findingsGlucagon-like peptide-1 as a recovery biomarker after traumatic brain injury in patients with obesity: Preliminary results.

📖 Top 20% JournalArticle

5 days ago • Journal of the American Geriatrics Society

Safe and Personalized Use of Weight Loss Medicines in Older Adults Using the Geriatrics 5Ms ApproachObesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.

Article

5 days ago • Diabetes, obesity & metabolism

Patterns of Digital Food Purchases and Their Changes with GLP-1 Treatment in People with ObesityDigital Food Purchase Signatures and Their Response to GLP-1-Based Treatment in People With Obesity.

Article

5 days ago • Endocrine

Comparing reported side effects of semaglutide and tirzepatide using FDA safety dataComparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS.

Comparative Study

5 days ago • Diabetes research and clinical practice

Semaglutide compared to other similar diabetes drugs and heart risk in cancer survivors with obesitySemaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors.

🎖️ Top 10% JournalArticle

← prevpage 2 of 16next →

Latest GLP-1 Therapies Research Papers